ESTRO 2024 - Abstract Book

S2266

Clinical - Upper GI

ESTRO 2024

Results:

Moderate quality of evidence was found (4 phase II and 0 phase III trials) resulting in weak recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with ≤3 metastases or 1 involved extra -regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression of disease after systemic therapy. 18F-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and DFI ≤2 years, treatment consists of systemic therapy followed by restaging to assess suitability of local treatment. For patients with metachronous OMD and DFI >2 years, upfront local treatment could also be performed.